Abstract: This invention relates to compounds (e.g., those delineated herein), pharmaceutically acceptable salts, prodrugs, solveates, and hydrates thereof. This invention also provides compositions comprising a compound of this invention and the use of such compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering modulating compounds or compositions that modulate A?, PAMPS and DAMPS.

Abstract: This invention relates to compounds (e.g., those delineated herein), pharmaceutically acceptable salts, prodrugs, solveates, and hydrates thereof. This invention also provides compositions comprising a compound of this invention and the use of such compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering modulating compounds or compositions that modulate A?, PAMPS and DAMPS.

Abstract: This invention relates to compounds (e.g., those delineated herein), pharmaceutically acceptable salts, prodrugs, solvates, and hydrates thereof. This invention also provides compositions comprising a compound of this invention and the use of such compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering modulating compounds or compositions that modulate A?, PAMPS and DAMPS.

Abstract: This invention relates to compounds (e.g., those delineated herein), pharmaceutically acceptable salts, prodrugs, solvates, and hydrates thereof. This invention also provides compositions comprising a compound of this invention and the use of such compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering modulating compounds or compositions that modulate A?, PAMPS and DAMPS.

Abstract: This document relates to methods and materials for treating diseases and disorders that are caused by or associated with amyloid or amyloid-like proteins, such as Alzheimer's disease. For example, methods and materials for using interleukin-6 to reduce or suppress the deposition of A? are provided.

Abstract: This document provides methods and materials related to anti-amyloid antibodies. For example, anti-amyloid antibodies, methods for making anti-amyloid antibodies, and methods for using an anti-amyloid antibody to treat or prevent an amyloid condition (e.g., AD) are provided.

Abstract: This document relates to methods and materials for reducing A?42 levels, reducing A? aggregation, or reducing both A?42 levels and A? aggregation. For example, this document provides methods and materials related to the use of agents (e.g., 5?-cholanic acid) to reduce A?42 levels and to reduce A? aggregation in mammals.

Abstract: This document relates to methods and materials for reducing A? aggregation. For example, methods and materials related to the use of BRI polypeptides (e.g., BRI2 polypeptides) and fragments of BRI polypeptides (e.g., a BRI23 polypeptide) to reduce A? aggregation in mammals are provided.

Abstract: This document provides methods and materials related to anti-amyloid antibodies. For example, anti-amyloid antibodies, methods for making anti-amyloid antibodies, and methods for using an anti-amyloid antibody to treat or prevent an amyloid condition (e.g., AD) are provided.

Abstract: This document provides methods and materials related to anti-A? antibodies. For example, anti-A? antibodies, methods for making anti-A? antibodies, and methods for using an anti-A? antibody to treat or prevent an amyloid condition (e.g., AD).

Abstract: Compositions containing fibrillar aggregates of amyloidogenic polypeptides and adjuvants are described as well as methods of using such compositions to induce generic anti-amyloid immune responses in mammals.

Abstract: The invention provides a method of preventing, delaying, or reversing the progression of Alzheimer's disease by administering an A?42 lowering agent to a mammal under conditions in which levels of A?42 are selectively reduced, levels of A?38 are increased, and levels of A?40 are unchanged. The invention provides methods and materials for developing and identifying A?42 lowering agents. In addition, the invention provides methods for identifying agents that increase the risk of developing, or hasten progression of, Alzheimer's disease. The invention also provides compositions of A?42 lowering agents and antioxidants, A?42 lowering agents and non-selective secretase inhibitors, as well as A?42 lowering agents and acetylcholinesterase inhibitors.